FDA Center for Drug Evaluation & Research

Fen-Phen Information
... Fen-Phen Information. ... Other Fen-Phen Background Information: FDA Announces
Withdrawal Fenfluramine and Dexfenfluramine (9/15/97)

Fen-Phen Update
"FEN-PHEN" UPDATE (fenfluramine, phentermine, dexfenfluramine) Center
for Drug Evaluation and Research Food and Drug Administration

FDA Announces Withdrawal Fenfluramine and Dexfenfluramine
( FDA Announces Withdrawal Fenfluramine and Dexfenfluramine
(Fen-Phen). Other Fen-Phen Links.

Public Health Advisory--Phenfen
DEPARTMENT OF HEALTH & HUMAN SERVICES, Public Health Service. 08
July 1997, Food and Drug Administration Rockville, MD 20857.

http://www.fda.gov/cder/news/slides/fenphendata.pdf
Fenfluramine + phentermine 85 Fenfluramine alone 3 Dexfenfluramine alone
9 Fen + phen/Dexfen + phen 4 (includes 24 cases from Mayo article) Summary.

FDA Analysis of Cardiac Valvular Dysfunction
with Use of... Fenfluramine alone 3. Dexfenfluramine alone 9. Fen + phen/Dexfen
+ phen 4. (includes 24 cases from Mayo article).

Questions and Answers about Withdrawal of Fenfluramine
Back to "Fen-Phen" Page. Questions and Answers about Withdrawal of Fenfluramine
(Pondimin) and Dexfenfluramine (Redux).

Counts of Subjects and Cases from Echo-Prevalence Surveys
Counts of Subjects and Cases from Echo-Prevalence
Surveys. Dexfen+/-phen. Fen-phen.

PPT Slide
... Dexfen�Phen. Relative Risk. 0. 0. 0. 0. 0. 0. 0. Khan.
Total. Wadden. Rasmussen. Glicklich. Khan. Bowen. 1. 11.
21. 31. Fen-Phen.
 

Absolute Risk of Valvulopathy from Echo-Based Prevalence
Dexfen�Phen. Proportion with Valvulopathy. 0. 0. 0. 0. 0. 0. 0. Khan. Overall.
Wadden. Rasmussen. Glicklich. Khan. Bowen. 0. 0.1. 0.2. 0.3. 0.4. 0.5. 0.6.
Fen-Phen.

Letter - Pondimin
loss agents is not recommended. The addition of phentermine to PONDIMIN ("fen/phen")
is not an approved use of PONDIMIN. Potential safety concerns with the.

Letter - Pondimin & Redux
the result of heightened concern regarding potential side effects which have been
reported with concomitant use of fenfluramine and phentermine ("fen/phen").

Important Safety Information - 1997
Genotropin (recombinant somatropin) (Posted: 11/25/97) "Herbal Fen-Phen"(Posted:
11/6/97) Ionamin (phentermine resin) Ionamin (phentermine resin.

The Law Offices of Nadrich & Associates is a fifteen person law firm which does commit the necessary resources to fight any pharmaceutical corporation including the manufacturers of Redux and Pondimen and all other diet drugs. We work on a contingency fee basis. A contingency fee means we only obtain a fee if we make a recovery.  If we do not win the case or make a recovery our clients owe us nothing for our time, costs or expenses.  

With many decades of combined experience, the Law Offices of Nadrich & Associates,  and our highly experienced staff of trial attorneys, paralegals, investigators and law clerks have the expertise and ample resources to successfully research, investigate and litigate all of our clients Primary Pulmonary Hypertension claims. We promise every client that their claim will be reviewed diligently and carefully. If we take a case, we will work extremely hard to obtain the best possible result.  We can help you immediately.  All e-mail and form submissions will be responded to by a qualified member of our firm within 24 hours.